Serenex, which is focused on drug discovery and development using chemoproteomics technology, will work with MolecularNature, a drug discovery firm based in the United Kingdom.
The two firms have agreed to explore future drug development using compounds identified with the Serenex screen process. The companies said they would share intellectual capital and revenue opportunities.
“MolecularNature has a library of potentially important pharmaceutical compounds,” said Richard Kent, president and chief executive officer of Serenex. “Serenex technology will help fast-forward the drug discovery process, determining compounds with the most value and propelling commercial development.”